Modeling the Ocular Pharmacokinetics and Pharmacodynamics of Ranibizumab for Improved Understanding and Data Collection Strategies in Ocular Diseases
Investigative Ophthalmology & Visual Science · 2025
DOI: 10.1167/iovs.66.6.20 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, 2025. Written by Jessica R Crawshaw and 4 co-authors. Institution: Wolfson Centre for Mathematical Biology, Mathematical Institute, University of Oxford, Oxford, United Kingdom. Major MEDLINE topics: Ranibizumab, Angiogenesis Inhibitors, Aqueous Humor, Models, Biological. Cited 5 times so far (Crossref); 72 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Purpose
Improving our understanding of the ocular pharmacokinetics and pharmacodynamics of anti-vascular endothelial growth factor (VEGF) therapies, such as ranibizumab, is essential to enhance treatment strategies for a range of retinal diseases, and will help inform the development of novel anti-VEGF drug candidates.
Methods
In this study, we examine a two-compartment pharmacokinetic/pharmacodynamic model of an intravitreal ranibizumab injection to understand its impact on ocular VEGF suppression. We use Bayesian inference to infer the model parameters from aqueous humor data extracted from healthy cynomolgus macaques. We leverage this approach to explore various sources of uncertainty in the data, offering practical recommendations for minimizing avoidable uncertainty.
Results
The model provides a robust description of ranibizumab pharmacokinetics and pharmacodynamics, identifying the recovery region of the aqueous humor VEGF concentration-time profile as critical for the precise estimation of parameters. Our results advocate focusing on this region in future studies for optimal data collection. We consider standard data correction techniques to reduce the data uncertainty introduced by the lower limit of quantification, identifying the most preferable technique for this model and data. Using a Bayesian approach we obtain an inferred mean posterior distribution of 1459 ± 98 pM for the ranibizumab dissociation constant, a pharmacodynamic parameter with notable variability across the literature.
Conclusions
This study extends our understanding of the ocular pharmacokinetics and pharmacodynamics of ranibizumab and provides theoretical insights for enhanced data collection schemes to be considered for clinical trials and in the development of novel anti-VEGF therapies.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Wolfson Centre for Mathematical Biology, Mathematical Institute, University of Oxford, Oxford, United Kingdom.
- Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Switzerland.
Cite
APA
Crawshaw, J. R., Gaffney, E. A., Gertz, M., Maini, P. K., & Caruso, A. (2025). Modeling the Ocular Pharmacokinetics and Pharmacodynamics of Ranibizumab for Improved Understanding and Data Collection Strategies in Ocular Diseases. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.66.6.20
Vancouver
Crawshaw JR, Gaffney EA, Gertz M, Maini PK, Caruso A. Modeling the Ocular Pharmacokinetics and Pharmacodynamics of Ranibizumab for Improved Understanding and Data Collection Strategies in Ocular Diseases. Investigative Ophthalmology & Visual Science. 2025. doi:10.1167/iovs.66.6.20
BibTeX
@article{Crawshaw2025,
author = {Crawshaw, Jessica R and Gaffney, Eamonn A and Gertz, Michael and Maini, Philip K and Caruso, Antonello},
title = {Modeling the Ocular Pharmacokinetics and Pharmacodynamics of Ranibizumab for Improved Understanding and Data Collection Strategies in Ocular Diseases},
journal = {Investigative Ophthalmology & Visual Science},
year = {2025},
doi = {10.1167/iovs.66.6.20}
}
EUVIMED